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ABSTRACT 
This paper reports a detailed comparison of a range of different types of 2D 
fingerprints when used for similarity-based virtual screening with multiple reference 
structures.  Experiments with the MDL Drug Data Report database demonstrate the 
effectiveness of fingerprints that encode circular substructure descriptors generated 
using the Morgan algorithm.  These fingerprints are notably more effective than 
fingerprints based on a fragment dictionary, on hashing and on topological 
pharmacophores.  The combination of these fingerprints with data fusion based on 
similarity scores provides both an effective and an efficient approach to virtual 
screening in lead-discovery programmes. 
 
 
 2 
INTRODUCTION 
 
Virtual screening is widely used to enhance the cost-effectiveness of drug-discovery 
programmes, by ranking databases of chemical structures in decreasing probability 
of activity; this prioritisation then means that biological testing can be focussed on 
just those few molecules that have significant a priori probabilities of activity [1, 2].  
There are many different ways in which a database can be prioritised; here, we focus 
on similarity searching methods [3, 4].  Similarity searching is one of the most 
widely used virtual-screening approaches, and involves matching a known active 
molecule, the reference structure, against each of the database molecules, 
computing a measure of structural similarity in each case, and then ranking the 
database molecules in order of decreasing similarity score.  Structurally similar 
molecules are likely to have similar biological activities [5-7] and there is hence an 
extensive literature associated with the similarity measures that can be used to 
quantify the degree of resemblance between a reference structure and each of the 
database molecules.   
 
Most of the studies of similarity searching that have been reported thus far have 
considered the use of only a single bioactive reference structure.  It is, however, 
increasingly the case that several, structurally diverse, reference structures may be 
available, e.g., published competitor compounds or hits from high-throughput 
screening (HTS), and this has stimulated interest in the use of multiple reference 
structures to identify further molecules for biological screening [8, 9].  We have 
recently reported a detailed comparison of several different search algorithms that 
can be used in such circumstances, and identified two, data fusion and binary kernel 
discrimination (BKD), that provided a high level of effectiveness in simulated 
virtual screening experiments [10].   
 
An important component of any similarity procedure is the structure representation 
that is used to encode the molecules that are to be searched, with 2D fragment bit-
strings (or fingerprints) of various types being by far the most commonly used in 
current chemoinformatics systems [11, 12].  A fingerprint is a binary string that 
encodes the presence of substructural fragments, i.e. topological patterns of atoms 
and bonds, in a molecule.  This is clearly a very simple representation of molecular 
structure but one that has been used with considerable success ever since the earliest 
reports of similarity searching [13, 14], and also for related chemoinformatics tasks 
such as molecular diversity analysis [15] and database clustering [16].  In two much-
cited papers, Brown and Martin compared several different types of fingerprint 
when used for cluster-based physicochemical property prediction [17, 18]; here, we 
report an analogous comparison of fingerprints when they are used for similarity-
based virtual screening using multiple reference structures. 
 
 
RESULTS AND DISCUSSION 
 
Taking account of the different search algorithms, fingerprint types and 
normalisation schemes described in the EXPERIMENTAL section, there is a total of 
30 different similarity procedures available for evaluation.  Each such procedure was 
used with each of 11 different activity classes from the MDL Drug Data Report 
(MDDR) [19] database, with ten searches being carried out for the actives in each 
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particular activity class.  A different set of ten active reference structures was used 
for each of the ten searches, this set remaining constant across the 30 different 
similarity procedures.  The results of the searches are shown in Tables 1-4, the first 
two listing the average recall obtained from the top-1% of the rankings for each of 
the activity classes, and the second two listing the average recall from the top-5% of 
the rankings.  The mean recalls, averaged over all of the 11 activity classes, are 
shown in Figures 1 and 2 (which also show the mean recall for data fusion and BKD 
averaged over all of the different fingerprint types considered here). 
 
Inspection of these tables reveals the very marked superiority of the circular 
substructure descriptors; indeed, there was only a single case where one of these 
fingerprints did not provide the best result, viz the average recall at 1% using BKD 
for the set of cyclooxygenase inhibitors.  This general effectiveness of the circular 
substructures (with the notable exception of FCFP_2) is highlighted in Figures 1 and 
2.  Of these circular substructure fingerprints, the ECFP_4 ones, irrespective of the 
normalisation method (method-A or method-B) or of the search algorithm (data 
fusion or BKD) are the descriptors of choice for virtual screening of the sort 
advocated here.  The FCFP_4 and ECFP_2 descriptors are also very effective: the 
former fingerprints seem to perform relatively better with the more heterogeneous 
(i.e., low self-similarity) classes, such as the cyclooxygenase and protein kinase C 
inhibitors, while the ECFP_2 fingerprints yield better results with the more 
homogeneous (i.e., high self-similarity) classes, such as the renin inhibitors.   
 
As an alternative way of considering the figures in Tables 1-4, consider the 
enrichment factors [20] to which these results correspond.  The enrichment factor is 
the number of times better (in terms of active molecules retrieved) that a particular 
search algorithm is than a random selection of molecules from the database.  Thus, 
the average enrichment values for ECFP_4B at 1% are 42.3 and 43.5 for BKD and 
data fusion, respectively, with the corresponding 5% values being 13.1 and 13.5, 
respectively, demonstrating the utility of the methods discussed here for virtual 
screening purposes.  
 
Circular substructures of various sorts have been widely used for applications such 
as structure and substructure searching [21-23], constitutional symmetry [24], 
structure elucidation [25] and, most recently, probabilistic modelling of bioactivity 
where a full training-set is available [26, 27].  The work reported here demonstrates 
that this type of fragment is also very well suited to virtual screening using multiple 
reference structures.   
 
When comparing the normalisation methods used for the circular substructure 
representations (see EXPERIMENTAL section), method A, where all the initial 
features are just assigned a new bit-position, always provides descriptors that are 
more effective than method B.  However the differences are generally very small, 
and we would hence recommend the use of method-B for the processing of these 
descriptors as this method is faster and, more importantly, is reproducible over 
different databases.  There is little to choose between data fusion and BKD over the 
entire class of circular substructures, although it does appear that the use of these 
substructures with data fusion was particularly successful for the more 
heterogeneous classes like the cyclooxygenase and protein kinase C inhibitors.  
Conversely, when these descriptors were used with BKD, they worked particularly 
 4 
well for the more homogeneous activity classes, such as the renin inhibitors and the 
angiotensin II AT1 antagonists. 
 
The dictionary-based descriptors, represented here by the BCI fingerprints, were 
ranked second overall, returning generally higher recalls than the hashed 
fingerprints, i.e., Unity, Daylight and Avalon.  This finding is in agreement with the 
studies of cluster-based property prediction by Brown and Martin [17, 18] (although 
they used different types of dictionary and hashed fingerprints from those studied 
here).   
 
Perhaps our most surprising finding is the performance of the pharmacophore 
descriptors, with both the CATS and Similog fingerprints yielding consistently 
poorer recall values.  Previous studies of these descriptors, for chemogenomics and 
scaffold-hopping applications [9, 28, 29], have demonstrated that they can be highly 
effective in operation, but this was certainly not the case for the present application.  
We note in the EXPERIMENTAL section that both of these molecular 
characterisations are based on the encoding of the occurrences, rather than the 
incidences, of substructural fragments in a molecule, yielding an integer vector 
rather than a binary fingerprint.  Here, however, they have been encoded in a binary 
form since the kernel function used in our BKD implementation requires a binary 
string.  It is hence possible that the poor performance of the two pharmacophore 
fingerprints arose from the use of an inappropriate encoding mechanism.  To test 
this, searches were carried out with the original, occurrence-based vectors; these 
searches used just data fusion, as this search algorithm does not necessarily require 
binary fingerprints for the generation of the ranked sets of scores that are fused 
together.  Specifically, the rankings for the individual reference structures were 
computed using the non-binary form of the Tanimoto similarity coefficient and the 
Floersheim distance, as defined in EXPERIMENTAL below.  The use of the integer 
vectors and the non-binary coefficients did not improve the recall of the data fusion 
searches, and we hence conclude that the use of binary representations does not 
explain the poor performance of these 2D pharmacophore descriptors that is 
observed in Tables 1-4.  It is perhaps worth noting in passing that previous 
comparisons of 2D fingerprints with 3D pharmacophore descriptors have often 
shown the former to be superior [17, 18, 30], despite the claimed effectiveness of the 
latter methods for diversity analysis and similarity searching [31].  
 
Thus far, we have evaluated the various approaches solely in terms of the numbers 
of active molecules that have been retrieved.  It is, however, also of importance to 
consider the diversity of these sets of retrieved actives, since it is clearly preferable 
for the outputs also to maximise the numbers of chemotypes that are identified.  We 
have hence analysed the outputs summarised in Tables 1-4 and Figures 1 and 2 in 
terms of the numbers of distinct ring systems identified in the sets of retrieved 
actives.  We have considered two levels of ring description, as illustrated in Figure 
3, and as discussed previously by Bemis and Murcko [32] and by Xu and Johnson 
[33, 34]; these authors refer to these levels of description as molecular frameworks 
or cyclic systems (Figure 3a), and frameworks or skeletal cyclic systems (Figure 
3b), respectively.  Figure 4 shows the percentages of the molecular frameworks in 
the complete set of actives that are retrieved in the top-1% of the ranking by each of 
the search procedures when averaged over all of the activity classes (i.e., as in 
Figure 1); Figure 5 gives the top-1% distribution for the frameworks and Figures 6 
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and 7 the corresponding top-5% distributions.  It will be seen that the relative 
performance of the various procedures in terms of retrieving chemotypes (and hence 
in their suitability for scaffold-hopping applications) mirrors closely the relative 
performance based on numbers of actives (as shown in Figures 1 and 2). 
 
All the experiments carried out so far were performed using a version of the MDDR 
database in which every molecule was characterised by its neutral structure.  
However, drugs are used in vivo and further searches were hence carried out in order 
to see if any improvements in recall could be obtained by using the protonated states 
of the MDDR molecules.  The pH component of Scitegic’s Pipeline Pilot software 
[35] was used to derive protonated molecular representations corresponding to a pH 
6.8.  However, very little difference was observed in the recalls obtained from the 
compounds in their protonated and neutral forms, with the latter normally being the 
more effective.  There would hence appear to be little point in carrying out the 
additional processing required to produce the protonated representations.   
 
The results presented here provide further evidence of the general effectiveness of 
the BKD and data fusion methods for virtual screening applications where multiple 
reference structures are available, and evidence of the general effectiveness of 
fingerprints based on 2D circular substructures, in particular the ECFP_4 
fingerprints.  If a single choice is required, then the best overall performance would 
seem to result from data fusion of the similarity scores of searches based on the 
ECFP_4B fingerprints.  This is indicated as the combination of choice for several 
reasons.  If we consider the choice of fingerprint first, then whilst the ECFP_4 
descriptors achieved an excellent overall level of performance, they gave 
particularly good results when searching for structurally heterogeneous sets of 
molecules, a more challenging task than for highly self-similar sets of molecules.  
For this descriptor, the type-B binning scheme results in a very compact, 
reproducible representation that is only marginally inferior to the much larger, non-
reproducible type-A binning scheme.  Turning now to the search algorithms: data 
fusion is far less demanding of computational resources than is BKD and also does 
not require the specification of values for the latter’s tuneable parameters; and an 
inspection of the standard deviations in Tables 1-4 shows that these tend to be larger 
(corresponding to a high level of variation in search performance) for BKD than for 
data fusion, suggesting a greater degree of consistency for the latter algorithm.   
 
When considering the two search algorithms, it must be emphasised that we are 
dealing with a combination of characteristics, as evidenced by the fact that BKD 
does better than data fusion for some of the fingerprint types (e.g., Unity or 
Daylight): however, when used in combination with ECFP_4, the data fusion 
searches are to be preferred.  It should also be emphasised that this preference for 
score-based data fusion over BKD is specific to the circumstances of these 
experiments, which involve just a limited number of active reference structures, as 
we have found that BKD is to be preferred when a proper training-set is available 
containing large numbers of both known actives and known inactives [36]. 
 
 
EXPERIMENTAL 
 
Our virtual screening system involves three main parts: a structural representation 
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that is used to encode the molecules that are being searched; a searching method that 
ranks a database of molecules in order of decreasing probability of activity in 
response to a set of active reference structures; and a quantitative measure of the 
effectiveness of those rankings.  The focus of this paper is the first of these factors, 
but it is appropriate to describe briefly the last two factors before discussing the 
many different types of 2D fingerprint that were evaluated. 
 
Searching algorithms 
A previous study [10] investigated a range of search algorithms that could be used 
when multiple reference structures were available.  These experiments all involved a 
single type of fingerprint, specifically the Unity fingerprints produced by Tripos Inc. 
[37].  Two of the algorithms were found to provide a consistently high level of 
screening effectiveness: these algorithms were data fusion using the maximum of 
similarity scores and an approximate form of the BKD machine learning technique.    
 
Data fusion (or consensus scoring) involves combining the results of different 
similarity searches of a chemical database.  Previous studies have involved the use 
of a single reference molecule, but characterised by several different representations 
or using several different similarity coefficients (see, e.g., [38, 39]).  An alternative 
approach, and the one used here, is to have a fixed representation and similarity 
coefficient, but to combine the search outputs obtained with several different 
reference structures.  Assume that some database molecule i yields similarity scores 
of s1, s2..sn with the n different reference structures, then we have shown that 
effective searches are obtained by ranking the database molecules on the basis of the 
maximum of these scores, i.e., max{s1, s2..si..sn-1, sn}; such searches are more 
effective than those resulting from the use of ranks, rather than scores, or the use of 
a fusion rule based on averaging [9, 10].   
 
The similarity scores were computed using the Tanimoto coefficient; for a molecule 
having a fingerprints with a bits set, of which c are also set in the fingerprint for a 
molecule that has b bits set, then the Tanimoto coefficient, Tc, is defined to be 
cba
cTc
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which is a Novartis coefficient that has been used in-house with the Similog 
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descriptors.  
 
Binary kernel discrimination (BKD) is a machine learning technique that was first 
applied to virtual screening by Harper et al. [40].  The similarity between two 
compounds i and j, characterised by binary fingerprints of length M, that differ in dij 
positions, is computed by the kernel function Kl(i,j),  
( )( ) MkddM ijijjiK /1),( lll -= -  
where l is a smoothing parameter to be determined and where k is an integer less 
than M.  This kernel was developed for use with a training-set containing both active 
and inactive molecules, with the scoring function 
å
å
Î
Î=
inactivesi
activesi
jiK
jiK
jL
),(
),(
)(
l
l
l  
being used to rank the molecules in the test-set, using the optimum values of l and k 
found for the training set [36].  When just a set of active reference structures is 
available, we have shown that the characteristics of the inactives can be 
approximated with a fair degree of accuracy by the characteristics of the entire 
database that is to be searched: a training-set can hence be generated by taking the 
set of reference structures and adding to it 100 molecules randomly selected from 
the database [10].  The optimal values of l and k were found to vary across the 
various types of fingerprint studied here, and extensive preliminary testing was 
required to identify the values that were used to obtain the main results that are 
discussed in RESULTS AND DISCUSSION.  This variation in parameter value is a 
clear limitation of the BKD approach  
 
Effectiveness of virtual screening 
The experiments involved simulated virtual screening searches on the MDL Drug 
Data Report (MDDR) database [19].  After removal of duplicates and molecules that 
could not be processed using local software, a total of 102,535 molecules was 
available for searching that were represented by each of the types of fingerprint 
described below.  These molecules were searched using the eleven sets of active 
compounds that are listed in Table 5, which also contains the numbers of actives in 
each class and the numbers of active assemblies and frameworks (ring-system 
descriptors that are discussed in RESULTS) in each class.  The table also contains a 
numeric estimate of the level of structural diversity in each of the chosen sets of 
bioactives.  The diversity estimate was obtained by matching each compound with 
every other in its activity class, calculating similarities using the Unity fingerprint 
and Tanimoto coefficient and computing the mean of these intra-set similarities.  
The resulting similarity scores are listed in the right-hand part of Table 5, where it 
will be seen that the renin inhibitors are the most homogeneous and the 
cyclooxygenase inhibitors are the most heterogeneous.  
 
For each of the 11 activity classes, ten active compounds were selected for use as 
reference structures.  The selections were done at random, subject to the constraint 
that no pair-wise similarity in a group exceeded 0.80 (using Unity fingerprints and 
the Tanimoto coefficient).  The set of reference structures was searched against the 
MDDR database using the data fusion and BKD search algorithms described above, 
with the search being carried out once for each of the different types of fingerprint.  
The procedure was then repeated using ten different sets of reference structures, and 
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in each search, a note was made of the recall, that is the percentage of the active 
molecules (i.e., those in the same class as those in the reference set) that occurred in 
the top-1% and the top-5% of the ranking resulting from that search.  Formally, if a 
search retrieves the top-x% of a ranked database, and that this subset contains a of 
the A actives for that activity class, then the recall, Rx, is defined to be [20] 
A
aRx ´= 100 . 
The results presented in Tables 1-4 are the mean and standard deviations for these 
recall values, averaged over each set of ten searches.   
 
Fingerprint types 
Having summarised the virtual screening environment and the two search 
algorithms, we now describe in some detail the four classes of fingerprint 
descriptors that we have studied.  These are structural keys, hashed fingerprints, 
circular substructures and pharmacophores; in all, we evaluated ten different 
descriptors, of which seven are commercially available, two are used in-house at 
Novartis, and one was implemented from the literature description.  Moreover, some 
of these descriptors were encoded in more than one way, to give a total of 15 types 
of fingerprint.  
 
Structural keys have been used in chemoinformatics for many years, and are usually 
encoded by a binary array, each element of which denotes the presence or absence of 
a specific 2D fragment.  A predefined fragment dictionary lists the various fragment 
substructures that are encoded in the fingerprint.  This study used the 1052-bit 
Barnard Chemical Information (BCI) fingerprints, which encode the following types 
of fragment substructure: augmented atoms, atom sequences, atom pairs, ring 
composition and ring fusion substructural fragments [41]. 
 
Hashed fingerprints differ from structural keys in that they do not use a predefined 
dictionary.  Instead, patterns are encoded in the fingerprint, where a pattern 
describes, for example, a path of length n bonds, i.e., (atom-bond-atom)n with the 
natures of the atoms and bonds defined.  The set of patterns produced from any 
molecule of non-trivial size is obviously very large and differs from molecule to 
molecule.  It is hence not possible to assign each potential pattern to a specific bit 
position in a fingerprint of predefined length; instead, the pattern is passed to a 
hashing function to generate a position (or positions) within the available length of 
the bit-string.  The study used three different hashed fingerprints: 2048-bit Daylight 
fingerprints [42], 988-bit Unity fingerprints [37] and 2048-bit Avalon fingerprints.  
Daylight fingerprints encode each atom’s type, all augmented atoms and all paths of 
length 2-7 atoms.  Unity fingerprints encode paths of length 2-6 atoms, and also 
include 60 structural keys for common atoms and ring counts.  Avalon fingerprints 
are used for similarity search in Novartis’ corporate data warehouse and encode 
atoms, augmented atoms, atom triplets and connection paths.  
 
A circular substructure is a fragment descriptor where each atom is represented by a 
string of extended connectivity values that are calculated using a modification of the 
Morgan Algorithm [43].  The study evaluated two different circular substructure 
descriptors from Scitegic’s Pipeline Pilot Software [35]: Extended Connectivity 
Fingerprints (ECFPs) and Functional Connectivity Fingerprints (FCFPs).  The initial 
code assigned to an atom is based on the number of connections, the element type, 
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the charge, and the mass for ECFPs and on six generalised atom-types - viz., 
hydrogen bond donor, hydrogen bond acceptor, positively ionisable, negatively 
ionisable, aromatic and halogen - for FCFPs.  This code, in combination with the 
bond information and with the codes of its immediate neighbour atoms is hashed to 
produce the next order code, which is mapped into an address space of size 232, and 
the process iterated until the required level of description has been achieved.  The 
experiments here used the ECFP_2, ECFP_4, FCFP_2 and FCFP_4 fingerprints, 
where the numeric code denotes the diameter in bonds up to which features are 
generated.  
 
The Scitegic software represents a molecule by list of integers, each describing a 
molecular feature and each in the range -231 to 231.  These integer lists were 
normalised in two ways, referred to as method-A and method-B.  In method-A, all 
the features present in the database were enumerated, so that each feature was given 
as its new code its rank in the sorted list of codes, with the length of the resulting 
fingerprints being the number of distinct features in the database.  In method-B, the 
integers describing a molecule were hashed to a bit-string of length 1024 bits.  This 
inevitably means that collisions occur, with the result that method-B loses some of 
the structural information that is retained by method-A; however, the latter 
representation is dependent on the precise database that is being processed.   
 
Pharmacophore points are features (such as a heteroatom or the centre of an 
aromatic ring) that are thought to be required for a molecule to show bioactivity.  
Pharmacophore fingerprinting involves generating all of the patterns of three or four 
pharmacophore points in a molecule, together with the corresponding inter-point 
distances, and then using the resulting 3D structural codes as descriptors for 
similarity searching or diversity analysis (see, e.g., [17, 18, 30, 31]).  When used 
with 2D, rather than 3D, structural representations, the inter-atomic distances can be 
replaced by through-bond distances, and this approach forms the basis of the two 
pharmacophore fingerprints studied here: Similog keys [9] and the Chemically 
Advanced Template Search (CATS) descriptor [28], both of which are based on 
generalised atom-types describing potential pharmacophores. 
 
The Similog keys use a “DABE” atom-typing scheme based on the following four 
properties: hydrogen bond donor (D), hydrogen bond acceptor (A), bulkiness (B) 
and electropositivity (E).  The presence or absence of these properties for an atom is 
encoded in a 4-bit string, and each triplet of atoms is represented by the three DABE 
strings and by the associated topological distances: in all, 8031 different codes were 
identified in the MDDR database.  The Similog keys store the occurrence of each 
distinct code, and not just their presence or absence as in a conventional bit-string.  
A binning scheme was hence used to bin the occurrence data into 8-bit strings: the 
two binning schemes used (called Method-A and Method–B) are shown in Table 2 
 
The CATS descriptor is based on counts of atom-pair topological distances, with the 
following generalised types of atom being considered in the generation of the 
descriptor: lipophilic, positive, negative, hydrogen-bond donor and hydrogen-bond 
acceptor.  The occurrences of the 15 possible pairs of pharmacophores are 
determined for distances up to 10 bonds to give a 150-element (i.e., 15 × 10) vector.  
The vectors were generated using the description in Fechner et al. [29] and then 
converted to a binary fingerprint using Method-B in Table 6 (we only used Method-
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B for CATS as a substantial fraction of the keys occurred more than seven times in a 
molecule). 
 
Table 7 lists the abbreviated names that are used in the paper for each of the 15 
types of fingerprints, where the A and B subscripts denote the type of normalisation 
scheme used for binning in the case of the ECFP, FCFP and Similog descriptors.  
The table also details statistical characteristics of each of these fingerprints: an 
inspection of the average numbers of bits and the densities (i.e., the mean number of 
bits that are set divided by the bit-string length and then expressed as a percentage) 
show a very wide range of levels of molecular description. 
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Figure 1.  Comparison of the average recalls at 1% obtained using the BKD and the 
data fusion approaches 
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Figure 2.  Comparison of the average recalls at 5% obtained using the BKD and the 
data fusion approaches 
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Figure 3.  Example of (a) molecular framework (or cyclic system) and (b) framework 
(or skeletal cyclic system) of Diovan® 
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Figure 4.  Comparison of the average percentage of molecular frameworks retrieved 
in the top 1% of the ranked test set obtained using BKD and data fusion. 
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Figure 5.  Comparison of the average percentage of frameworks retrieved in the top 
1% of the ranked test set obtained using BKD and data fusion. 
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Figure 6.  Comparison of the average percentage of molecular frameworks retrieved 
in the top 5% of the ranked test set obtained using BKD and data fusion. 
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Figure 7.  Comparison of the average percentage of frameworks retrieved in the top 
5% of the ranked test set obtained using BKD and data fusion. 
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Activity Classes BCI  Daylight  Unity  Avalon  SimilogA  SimilogB  CATS Mean SD  Mean SD  Mean SD  Mean SD  Mean SD  Mean SD  Mean SD 
5HT3 antagonists 35.51 3.32  27.55 4.97  28.99 6.12  34.91 4.84  34.58 11.25  41.28 10.60  11.79 2.50 
5HT1A agonists 27.41 6.36  21.70 4.90  19.52 3.88  21.29 5.70  16.22 5.41  20.07 6.20  9.02 2.14 
5HT Reuptake inhibitors 25.50 5.57  29.28 6.80  27.82 6.61  24.44 6.28  19.40 6.21  22.15 6.86  9.60 1.86 
D2 antagonists 27.12 4.92  24.86 6.31  23.19 5.57  23.30 4.57  17.95 3.75  21.61 3.85  10.52 4.02 
Renin inhibitors 65.14 8.73  61.60 7.25  62.29 5.50  62.98 4.42  32.35 18.85  32.32 15.73  43.00 10.35 
Angiotensin II AT1 antagonists 47.12 2.31  47.73 2.58  47.19 2.05  45.89 2.58  36.78 6.68  36.10 4.56  38.55 6.39 
Thrombin inhibitors 39.04 7.01  32.60 5.58  33.69 7.05  36.54 7.41  11.16 5.93  11.26 6.22  30.44 8.53 
Substance P antagonists 31.98 6.09  33.01 5.47  31.68 3.98  22.56 4.44  15.70 6.51  15.39 6.90  7.98 3.15 
HIV protease inhibitors 39.35 8.07  44.07 9.32  41.30 7.92  39.62 9.34  42.24 9.54  40.32 5.68  25.62 8.81 
Cyclooxygenase inhibitors 24.58 5.10  21.23 5.27  20.80 4.22  20.99 2.82  16.21 2.66  16.52 3.64  10.45 2.52 
Protein kinase C inhibitors 33.39 7.56  38.10 9.04  36.93 9.73  36.43 10.25  31.65 10.93  29.07 10.42  16.73 6.66 
Average over all classes 36.01 5.91  34.70 6.14  33.95 5.69  33.54 5.70  24.93 7.97  26.01 7.33  19.43 5.18 
 
Activity Classes ECFP_2A  ECFP_2B  ECFP_4A  ECFP_4B  FCFP_2A  FCFP_2B  FCFP_4A  FCFP_4B Mean SD  Mean SD  Mean SD  Mean SD  Mean SD  Mean SD  Mean SD  Mean SD 
5HT3 antagonists 45.84 4.18  43.19 5.62  45.93 7.00  44.66 6.57  38.37 3.64  36.48 4.46  45.07 4.51  44.31 4.07 
5HT1A agonists 29.42 6.25  29.24 5.29  33.45 6.15  33.44 5.55  18.87 2.29  18.02 2.54  28.52 4.27  27.98 3.98 
5HT Reuptake inhibitors 31.78 5.88  31.20 4.89  32.81 6.09  31.00 6.36  29.57 4.03  28.94 4.40  33.58 6.90  33.52 7.06 
D2 antagonists 28.60 6.18  28.68 5.33  30.36 6.70  30.47 6.59  20.65 4.84  20.70 4.49  29.14 6.88  28.42 6.55 
Renin inhibitors 76.59 2.40  76.17 2.71  77.91 3.37  77.97 2.28  49.51 6.46  48.92 6.80  71.14 7.55  71.16 8.03 
Angiotensin II AT1 antagonists 49.00 3.03  49.95 3.01  49.57 3.36  49.80 2.98  44.93 2.16  45.22 1.89  48.31 3.18  48.71 3.23 
Thrombin inhibitors 43.91 11.88  43.46 11.99  41.98 9.36  41.41 9.26  34.89 8.12  34.07 7.50  39.89 6.68  39.71 6.30 
Substance P antagonists 35.56 6.30  37.00 6.01  38.29 9.33  37.38 9.22  28.33 5.26  27.66 5.48  35.26 6.39  34.72 6.26 
HIV protease inhibitors 52.41 8.49  51.59 7.64  55.28 8.63  56.28 7.89  34.93 7.04  35.34 7.97  44.77 8.25  44.64 8.52 
Cyclooxygenase inhibitors 23.07 3.25  22.11 3.25  22.80 3.62  22.35 3.73  20.48 3.33  20.34 3.16  24.46 5.04  23.75 4.60 
Protein kinase C inhibitors 37.45 10.93  37.67 9.95  39.95 11.89  40.14 9.75  35.94 7.42  34.94 9.65  40.34 11.50  40.07 11.31 
Average over all classes 41.24 6.25  40.93 5.97  42.58 6.86  42.26 6.38  32.41 4.96  31.88 5.31  40.04 6.47  39.73 6.36 
 
Table 1.  Comparison of the average recalls at 1% obtained with BKD  
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Activity Classes BCI  Daylight   Unity  Avalon  SimilogA  SimilogB  CATS Mean SD  Mean SD  Mean SD  Mean SD  Mean SD  Mean SD  Mean SD 
5HT3 antagonists 35.51 4.08  31.91 2.84  31.04 5.29  30.54 4.50  34.43 3.64  34.69 4.61  8.71 3.15 
5HT1A agonists 30.98 5.50  22.63 3.88  20.06 4.33  19.41 5.28  26.18 4.16  27.31 4.62  10.11 2.58 
5HT Reuptake inhibitors 28.74 4.38  30.86 5.48  29.03 4.83  31.78 3.37  27.88 5.92  27.99 5.49  9.37 2.87 
D2 antagonists 27.87 3.66  25.09 4.89  22.65 4.48  23.40 4.81  30.23 4.14  28.96 4.61  10.44 3.75 
Renin inhibitors 52.96 8.34  51.29 3.34  50.23 3.18  56.71 4.03  43.59 15.43  48.64 13.78  60.61 1.99 
Angiotensin II AT1 antagonists 43.10 2.95  43.44 3.03  41.39 4.04  42.96 4.74  44.15 1.82  44.96 1.79  40.15 2.21 
Thrombin inhibitors 36.25 9.31  27.59 7.37  27.74 9.23  34.15 9.85  17.65 9.82  20.38 9.90  22.47 14.04 
Substance P antagonists 23.82 5.82  24.66 5.07  23.07 4.61  17.96 4.76  19.69 6.82  20.19 6.63  9.27 2.30 
HIV protease inhibitors 25.57 6.77  33.14 8.17  33.78 7.21  33.07 7.86  39.51 5.24  39.84 4.66  27.89 7.36 
Cyclooxygenase inhibitors 22.59 6.38  19.76 4.88  18.48 4.83  19.04 4.65  17.24 1.32  16.57 1.57  7.83 1.22 
Protein kinase C inhibitors 33.91 8.87  41.31 8.24  39.23 6.61  38.42 6.30  27.72 9.41  27.79 9.32  16.03 4.76 
Average over all classes 32.84 6.01  31.97 5.20  30.61 5.33  31.59 5.47  29.84 6.16  30.67 6.09  20.26 4.20 
 
Activity Classes ECFP_2A  ECFP_2B  ECFP_4A  ECFP_4B  FCFP_2A  FCFP_2B  FCFP_4A  FCFP_4B Mean SD  Mean SD  Mean SD  Mean SD  Mean SD  Mean SD  Mean SD  Mean SD 
5HT3 antagonists 47.33 3.40  45.98 3.06  52.18 4.99  50.77 4.99  32.82 2.81  30.70 3.02  44.16 3.82  44.00 3.45 
5HT1A agonists 30.89 5.56  30.81 5.28  35.83 4.42  34.99 3.91  20.21 1.38  20.13 1.90  29.17 3.31  29.16 3.09 
5HT Reuptake inhibitors 29.89 4.42  30.06 4.41  31.89 5.80  31.95 5.67  26.39 6.61  25.16 7.21  32.69 6.21  33.12 6.13 
D2 antagonists 27.95 6.18  27.58 6.19  31.84 5.42  31.90 5.78  21.06 4.42  20.42 5.00  29.74 5.51  29.22 5.18 
Renin inhibitors 72.21 4.79  72.11 3.81  75.10 4.59  75.01 3.96  45.79 5.32  44.85 5.56  65.64 6.51  65.58 6.92 
Angiotensin II AT1 antagonists 47.83 3.80  47.71 4.37  49.99 3.95  51.14 3.72  40.96 3.48  41.91 3.69  49.25 3.28  49.51 3.29 
Thrombin inhibitors 41.90 11.71  41.31 11.08  41.98 10.59  42.06 10.00  27.33 7.84  26.58 7.75  37.93 9.38  37.14 8.36 
Substance P antagonists 32.81 6.25  32.80 6.38  36.51 7.65  36.05 8.25  19.96 3.98  19.72 3.61  30.44 6.64  30.05 6.42 
HIV protease inhibitors 48.69 6.83  49.22 6.60  54.31 7.51  54.07 6.65  28.55 6.58  28.85 7.15  43.38 8.09  42.91 8.04 
Cyclooxygenase inhibitors 21.61 3.92  21.39 3.86  24.30 3.91  23.74 4.47  17.56 3.28  17.17 3.29  24.03 4.52  23.31 4.41 
Protein kinase C inhibitors 41.02 7.38  41.92 6.85  46.70 8.93  46.30 8.08  33.16 9.46  32.62 9.51  45.26 9.12  44.90 8.89 
Average over all classes 40.19 5.84  40.08 5.63  43.69 6.16  43.45 5.95  28.53 5.02  28.01 5.25  39.24 6.03  38.99 5.83 
 
Table 2.  Comparison of the average recalls at 1% obtained with data fusion 
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Activity Classes BCI  Daylight   Unity  Avalon  SimilogA  SimilogB  CATS Mean SD  Mean SD  Mean SD  Mean SD  Mean SD  Mean SD  Mean SD 
5HT3 antagonists 55.71 4.36  46.25 6.73  52.08 8.35  52.44 6.08  59.51 13.72  65.08 12.88  28.80 2.51 
5HT1A agonists 49.99 10.31  43.35 7.61  38.24 7.05  40.16 7.25  45.68 10.67  52.04 9.78  22.94 5.66 
5HT Reuptake inhibitors 42.61 8.85  44.56 10.50  45.36 8.66  40.63 10.98  38.25 9.14  44.99 8.29  25.73 5.15 
D2 antagonists 46.47 8.49  42.36 9.68  38.62 7.54  35.92 6.04  45.69 7.45  52.03 5.02  21.71 6.53 
Renin inhibitors 93.23 3.69  92.54 2.80  93.34 1.38  93.98 2.91  81.25 8.67  82.96 5.73  89.67 2.65 
Angiotensin II AT1 antagonists 90.92 2.31  88.87 3.43  84.47 6.61  80.58 4.21  71.52 9.94  70.99 8.06  75.68 5.05 
Thrombin inhibitors 68.98 5.31  61.30 8.12  63.01 7.60  69.19 7.30  37.35 13.03  37.12 11.53  60.83 8.43 
Substance P antagonists 51.89 9.11  57.01 5.23  58.37 8.25  44.46 7.96  36.13 8.73  33.06 8.55  19.41 4.62 
HIV protease inhibitors 66.47 6.73  67.32 9.76  68.41 8.34  60.92 12.82  70.39 8.31  69.93 6.80  60.91 9.18 
Cyclooxygenase inhibitors 36.02 6.55  32.30 5.48  33.13 4.59  32.04 4.23  30.75 6.43  30.89 6.80  22.49 2.92 
Protein kinase C inhibitors 45.15 7.85  48.35 9.48  49.16 10.98  47.90 8.12  45.67 9.58  46.00 8.33  30.02 7.33 
Average over all classes 58.86 6.69  56.75 7.17  56.74 7.21  54.38 7.08  51.11 9.61  53.19 8.34  41.65 5.46 
 
Activity Classes ECFP_2A  ECFP_2B  ECFP_4A  ECFP_4B  FCFP_2A  FCFP_2B  FCFP_4A  FCFP_4B Mean SD  Mean SD  Mean SD  Mean SD  Mean SD  Mean SD  Mean SD  Mean SD 
5HT3 antagonists 67.55 6.15  63.05 8.52  65.31 6.74  63.36 7.55  62.70 6.92  61.56 7.41  68.64 6.71  67.67 6.57 
5HT1A agonists 54.42 8.14  52.83 6.65  58.65 7.93  57.49 7.74  45.08 5.32  44.81 4.14  55.10 7.23  54.06 6.05 
5HT Reuptake inhibitors 50.54 4.00  49.11 2.90  50.26 5.88  49.00 6.53  49.77 3.66  50.43 3.95  50.49 5.69  50.14 7.01 
D2 antagonists 50.42 8.49  51.48 7.31  55.19 9.46  54.18 9.02  46.18 9.45  45.14 8.68  52.62 8.50  51.74 9.24 
Renin inhibitors 97.58 0.58  97.60 0.54  96.74 0.77  96.99 0.77  92.09 4.76  92.94 3.90  97.57 1.28  97.59 1.08 
Angiotensin II AT1 antagonists 97.02 1.66  96.86 1.72  97.97 0.80  97.81 0.58  86.84 5.48  87.33 5.15  94.97 4.66  95.09 4.14 
Thrombin inhibitors 77.60 8.71  75.08 9.96  74.79 8.77  74.07 8.01  69.90 5.85  67.89 6.96  74.12 6.92  73.77 6.37 
Substance P antagonists 61.97 8.17  62.74 7.66  67.31 9.50  65.51 10.24  48.78 6.49  48.09 8.10  59.80 7.93  59.10 9.06 
HIV protease inhibitors 79.32 7.72  79.07 7.13  80.78 6.00  80.76 5.02  62.66 9.46  63.39 9.98  70.49 11.83  70.61 12.21 
Cyclooxygenase inhibitors 35.99 5.42  34.55 5.25  34.35 5.44  32.67 6.20  36.71 4.66  35.62 4.78  36.93 6.20  36.47 6.79 
Protein kinase C inhibitors 49.21 11.44  49.89 11.15  49.57 13.65  50.29 8.85  48.22 7.79  49.41 8.09  49.73 12.72  49.10 12.06 
Average over all classes 65.60 6.41  64.75 6.25  66.45 6.81  65.65 6.41  58.99 6.35  58.78 6.47  64.59 7.24  64.12 7.33 
 
Table 3.  Comparison of the average recalls at 5% with BKD  
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Activity Classes BCI  Daylight   Unity  Avalon  SimilogA  SimilogB  CATS Mean SD  Mean SD  Mean SD  Mean SD  Mean SD  Mean SD  Mean SD 
5HT3 antagonists 58.80 5.89  51.33 3.49  49.03 5.43  52.36 4.05  49.51 7.74  48.81 8.41  20.85 6.19 
5HT1A agonists 54.71 5.77  40.88 5.59  37.16 4.05  34.71 4.74  48.75 6.14  49.82 7.12  23.01 3.64 
5HT Reuptake inhibitors 45.36 4.66  46.85 5.43  49.66 5.48  47.59 5.22  46.62 6.07  46.73 6.03  23.15 6.42 
D2 antagonists 48.26 4.38  42.42 6.60  37.40 4.92  33.30 6.03  53.14 7.68  50.29 7.23  21.77 5.14 
Renin inhibitors 93.54 1.30  90.10 1.95  88.62 1.90  90.00 4.02  85.53 2.69  87.54 2.58  91.14 1.49 
Angiotensin II AT1 antagonists 86.33 3.54  86.90 1.99  80.45 6.08  82.02 4.63  82.03 4.79  84.07 4.60  71.24 4.81 
Thrombin inhibitors 66.58 5.57  56.47 7.56  58.56 8.98  63.25 8.60  35.70 10.90  39.71 10.87  43.30 16.02 
Substance P antagonists 44.83 7.18  51.82 6.28  47.14 5.16  39.90 3.73  36.79 7.55  36.47 6.96  24.05 2.71 
HIV protease inhibitors 58.95 4.60  58.69 6.97  61.62 7.85  56.08 7.43  63.54 4.53  63.45 4.56  56.70 10.08 
Cyclooxygenase inhibitors 33.35 7.78  29.87 7.81  26.52 7.15  30.93 6.74  28.08 4.37  27.97 4.18  15.88 1.49 
Protein kinase C inhibitors 47.25 9.39  48.87 8.29  48.01 8.99  52.26 5.21  37.83 8.55  38.04 8.77  27.99 5.24 
Average over all classes 58.00 5.46  54.93 5.63  53.11 6.00  52.95 5.49  51.59 6.46  52.08 6.48  38.10 5.75 
 
Activity Classes ECFP_2A  ECFP_2B  ECFP_4A  ECFP_4B  FCFP_2A  FCFP_2B  FCFP_4A  FCFP_4B Mean SD  Mean SD  Mean SD  Mean SD  Mean SD  Mean SD  Mean SD  Mean SD 
5HT3 antagonists 69.66 4.84  68.54 4.88  72.24 6.05  70.38 6.42  54.49 3.32  53.21 3.21  66.46 5.68  65.80 5.17 
5HT1A agonists 55.73 6.50  55.65 6.30  64.19 4.45  63.17 4.60  45.48 3.94  45.80 4.00  55.40 4.54  55.72 3.86 
5HT Reuptake inhibitors 48.08 4.01  47.91 2.78  49.68 5.74  49.51 4.22  45.99 5.73  44.93 5.26  51.12 5.15  50.29 5.62 
D2 antagonists 50.29 5.98  48.94 5.26  56.05 5.39  54.70 5.90  44.36 5.86  45.58 6.10  50.60 6.22  51.17 5.84 
Renin inhibitors 97.27 0.72  97.35 0.63  96.76 0.72  96.92 0.87  88.61 3.09  87.60 3.52  97.22 0.85  97.04 0.74 
Angiotensin II AT1 antagonists 95.55 2.11  95.14 2.33  97.36 0.73  97.13 0.66  83.65 4.05  83.82 3.82  94.86 2.46  94.99 2.62 
Thrombin inhibitors 73.98 6.64  71.68 6.80  74.73 6.41  72.50 7.27  58.88 6.88  58.07 6.74  70.15 4.20  70.11 4.32 
Substance P antagonists 55.16 7.22  54.40 8.07  62.22 7.25  61.42 7.61  37.25 6.44  36.93 5.99  53.45 7.04  53.01 6.69 
HIV protease inhibitors 76.24 4.54  76.92 4.63  79.97 4.67  79.41 4.80  58.99 6.76  58.41 6.46  71.86 8.94  70.73 8.29 
Cyclooxygenase inhibitors 34.84 6.11  34.11 6.05  40.06 6.21  38.77 5.72  29.76 5.39  29.97 5.36  37.78 6.69  36.98 5.75 
Protein kinase C inhibitors 52.87 7.05  53.93 6.97  57.83 6.72  56.95 6.64  45.37 9.98  45.46 9.94  54.60 7.40  55.21 7.62 
Average over all classes 64.52 5.07  64.05 4.97  68.28 4.94  67.35 4.97  53.89 5.58  53.62 5.49  63.95 5.38  63.73 5.14 
 
Table 4.  Comparison of the average recalls at 5% with data fusion 
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Activity class Number Of Similarity Actives Assemblies Frameworks Mean SD 
5HT3 antagonists 752 438 237 0.351 0.116 
5HT1A agonists 827 478 271 0.343 0.104 
5HT Reuptake inhibitors 359 193 126 0.345 0.122 
D2 antagonists 395 270 187 0.345 0.103 
Renin inhibitors 1130 595 339 0.573 0.106 
Angiotensin II AT1 antagonists 943 496 285 0.403 0.101 
Thrombin inhibitors 803 451 295 0.419 0.127 
Substance P antagonists 1246 633 380 0.399 0.106 
HIV protease inhibitors 750 475 331 0.446 0.122 
Cyclooxygenase inhibitors 636 308 139 0.268 0.093 
Protein kinase C inhibitors 453 190 134 0.323 0.142 
 
Table 5.  MDDR activity classes used in the study 
 
 
 
Type A Type B 8-bit string 
1 occurrence 20 ≤ occurrences < 21 10000000 
2 occurrences 21 ≤ occurrences < 22 11000000 
3 occurrences 22 ≤ occurrences < 23 11100000 
4 occurrences 23 ≤ occurrences < 24 11110000 
5 occurrences 24 ≤ occurrences < 25 11111000 
6 occurrences 25 ≤ occurrences < 26 11111100 
7 occurrences 26 ≤ occurrences < 27 11111110 
8 and more occurrences 27 ≤ occurrences 11111111 
 
Table 6.  Binning schemes to convert the occurrence of Similog keys to incidences. 
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Name  Type Normalised Abbreviation Length Mean SD Max Min Density 
Barnard Chemical Information  Dictionary-based - BCI 1052 96.67 30.91 264 8 9.19 
Daylight  Hashed - Daylight 2048 289.45 111.21 1046 24 14.13 
Unity  Hashed - Unity 988 219.65 69.16 558 27 22.23 
Avalon  Hashed - Avalon 2048 285.06 149.31 1076 16 13.92 
ECFP_2  Circular substructure A ECFP_2A 7445 32.36 9.40 103 5 0.44 
ECFP_2  Circular substructure B ECFP_2B 1024 31.82 9.12 98 5 3.11 
ECFP_4  Circular substructure A ECFP_4A 142864 53.97 16.95 191 8 0.04 
ECFP_4  Circular substructure B ECFP_4B 1024 52.43 15.95 177 8 5.12 
FCFP_2  Circular substructure A FCFP_2A 600 20.88 5.00 47 5 3.48 
FCFP_2  Circular substructure B FCFP_2B 1024 20.41 4.83 45 5 1.99 
FCFP_4  Circular substructure A FCFP_4A 30267 40.63 11.14 122 7 0.13 
FCFP_4  Circular substructure B FCFP_4B 1024 39.44 10.55 113 7 3.85 
Similog  Pharmacophore A SimilogA 64248 1308.14 1437.17 14740 1 2.04 
Similog  Pharmacophore B SimilogB 64248 863.52 900.10 10101 1 1.34 
CATS  Pharmacophore - CATS 1200 95.99 36.18 453 1 8.00 
 
Table 7.  Comparison of the numbers of bits set in each of the 15 types of fingerprint evaluated in the study. 
